| Malignant neoplasm of ovary
Keytruda vs Cytalux
Side-by-side clinical, coverage, and cost comparison for malignant neoplasm of ovary.Deep comparison between: Keytruda vs Cytalux with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsCytalux has a higher rate of injection site reactions vs Keytruda based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Cytalux but not Keytruda, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Keytruda
Cytalux
At A Glance
IV infusion
Every 3 weeks or Every 6 weeks
PD-1 inhibitor
IV infusion
Single pre-surgical dose
Folate receptor-targeted imaging agent
Indications
- melanoma
- Non-Small Cell Lung Carcinoma
- Malignant Pleural Mesothelioma
- Squamous cell carcinoma of the head and neck
- Classic Hodgkin Lymphoma
- Mediastinal (Thymic) Large B-Cell Lymphoma
- Urothelial Carcinoma
- Colorectal Carcinoma
- Stomach Carcinoma
- Esophageal carcinoma
- Cervix carcinoma
- Liver carcinoma
- Biliary Tract Cancer
- Merkel cell carcinoma
- Renal Cell Carcinoma
- Endometrial Carcinoma
- Triple-Negative Breast Carcinoma
- Malignant neoplasm of ovary
- Squamous cell carcinoma of skin
- Malignant neoplasm of ovary
- Malignant neoplasm of lung
Dosing
melanoma 200 mg every 3 weeks or 400 mg every 6 weeks IV; 2 mg/kg (up to 200 mg) every 3 weeks IV for pediatrics
Non-Small Cell Lung Carcinoma 200 mg every 3 weeks or 400 mg every 6 weeks IV
Malignant Pleural Mesothelioma 200 mg every 3 weeks or 400 mg every 6 weeks IV
Squamous cell carcinoma of the head and neck 200 mg every 3 weeks or 400 mg every 6 weeks IV
Classic Hodgkin Lymphoma 200 mg every 3 weeks or 400 mg every 6 weeks IV for adults; 2 mg/kg (up to 200 mg) every 3 weeks IV for pediatrics
Mediastinal (Thymic) Large B-Cell Lymphoma 200 mg every 3 weeks or 400 mg every 6 weeks IV for adults; 2 mg/kg (up to 200 mg) every 3 weeks IV for pediatrics
Urothelial Carcinoma 200 mg every 3 weeks or 400 mg every 6 weeks IV
Colorectal Carcinoma 200 mg every 3 weeks or 400 mg every 6 weeks IV for adults; 2 mg/kg (up to 200 mg) every 3 weeks IV for pediatrics
Stomach Carcinoma 200 mg every 3 weeks or 400 mg every 6 weeks IV
Esophageal carcinoma 200 mg every 3 weeks or 400 mg every 6 weeks IV
Cervix carcinoma 200 mg every 3 weeks or 400 mg every 6 weeks IV
Liver carcinoma 200 mg every 3 weeks or 400 mg every 6 weeks IV
Biliary Tract Cancer 200 mg every 3 weeks or 400 mg every 6 weeks IV
Merkel cell carcinoma 200 mg every 3 weeks or 400 mg every 6 weeks IV for adults; 2 mg/kg (up to 200 mg) every 3 weeks IV for pediatrics
Renal Cell Carcinoma 200 mg every 3 weeks or 400 mg every 6 weeks IV as single agent or in combination with axitinib 5 mg orally twice daily or lenvatinib 20 mg orally once daily
Endometrial Carcinoma 200 mg every 3 weeks or 400 mg every 6 weeks IV in combination with carboplatin and paclitaxel, or with lenvatinib 20 mg orally once daily, or as single agent for MSI-H or dMMR tumors
Triple-Negative Breast Carcinoma 200 mg every 3 weeks or 400 mg every 6 weeks IV
Malignant neoplasm of ovary 200 mg every 3 weeks or 400 mg every 6 weeks IV
Squamous cell carcinoma of skin 200 mg every 3 weeks or 400 mg every 6 weeks IV
Malignant neoplasm of ovary 0.025 mg/kg single IV infusion diluted in 250 mL 5% Dextrose Injection, administered over 60 minutes via dedicated infusion line, 1 to 9 hours prior to surgery.
Malignant neoplasm of lung 0.025 mg/kg single IV infusion diluted in 250 mL 5% Dextrose Injection, administered over 60 minutes via dedicated infusion line, 1 to 24 hours prior to surgery.
Contraindications
—
Adverse Reactions
Most common (>=20%) fatigue, musculoskeletal pain, decreased appetite, rash, diarrhea, nausea, cough, dyspnea, constipation, pruritus, hypothyroidism
Serious pneumonitis, colitis, hepatitis, endocrinopathies, nephritis with renal dysfunction, dermatologic adverse reactions, myocarditis, neurological toxicities, infusion-related reactions, immune-mediated adverse reactions
Postmarketing exocrine pancreatic insufficiency, sclerosing cholangitis
Most common (>=1%) Nausea, vomiting, abdominal pain, flushing, other infusion-related reactions, hypersensitivity, elevation in blood pressure, dyspepsia, chest discomfort
Pharmacology
Pembrolizumab is a PD-1 blocking antibody that releases PD-1 pathway-mediated inhibition of the immune response by preventing the interaction of PD-1 with its ligands PD-L1 and PD-L2, thereby restoring anti-tumor immune response.
Pafolacianine binds to alpha and beta folate receptors on cells, is internalized via receptor-mediated endocytosis, and accumulates intracellularly, enhancing lesion visualization through the differential level of expression and accessibility of folate receptors within lesions relative to normal tissue.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Keytruda
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (0/12)
No coverage data available for Cytalux.
UnitedHealthcare
Keytruda
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
No coverage data available for Cytalux.
Humana
Keytruda
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
No coverage data available for Cytalux.
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Keytruda.
No savings programs available for Cytalux.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
KeytrudaView full Keytruda profile
CytaluxView full Cytalux profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.